Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor: A case report
Background: Melanoma accounts for 8% of all malignancies encountered during pregnancy. BRAF kinase inhibitors have shown promise in the treatment of late-stage melanoma; however, there have been no studies and only one previous case report regarding its use in pregnancy. Case: A 25-year-old woman, g...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2019-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Melanoma accounts for 8% of all malignancies encountered during pregnancy. BRAF kinase inhibitors have shown promise in the treatment of late-stage melanoma; however, there have been no studies and only one previous case report regarding its use in pregnancy. Case: A 25-year-old woman, gravida 1, at 20 weeks of gestation presented to the clinic with a complaint of a lump on her neck and dyspnea. She had had a melanoma that was surgically treated 5 years prior to her pregnancy. A biopsy was performed and she was found to have metastatic melanoma. After multidisciplinary discussion, the patient was offered treatment with vemurafenib, a BRAF kinase inhibitor, and the mass reduced in size. Conclusion: Malignancy during pregnancy poses both medical and ethical dilemmas in the management and treatment of cancer. The treatment of late-stage melanoma in pregnancy with a BRAF kinase inhibitor may be an option. Keywords: Melanoma, Pregnancy, BRAF inhibitor |
|---|---|
| Item Description: | 2214-9112 10.1016/j.crwh.2019.e00142 |